検索 メニュー MENU

× 閉じる

ソフトバンク・ビジョン・ファンド バイオ薬品事業Roivant Sciencesに11億ドル出資

 

Roivant Sciences Raises $1.1 Billion in Equity Investment Led

by SoftBank Vision Fund

 

Roivant Sciencesについて

Roivant is dedicated to transformative innovation in healthcare. Roivant focuses on realizing the full potential of promising biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. We partner with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients.

We advance our drug pipelines through wholly- or majority-owned subsidiary companies, including Axovant (neurology), Myovant (women’s health and endocrine diseases), Dermavant (dermatology), Enzyvant (rare diseases), and Urovant (urology). Roivant also plans to launch new companies operating outside of traditional biopharmaceutical development. Roivant’s long-range mission is to reduce the time and cost of developing and delivering new medicines for patients. For more information, please visit roivant.com.

 

出典:Roivant Sciences HPより

2017.08.26 更新